All Questions Answered for Ariad Pharmaceuticals Inc.
Shares of Ariad Pharmaceuticals fell today, but on Friday after a tremendous week filled with buyout speculation, Motley Fool health-care analyst David Williamson answered viewer questions about the biotech. Shares rose 12% on Thursday and 25% on Friday, on news of a rumor that Eli Lilly and GlaxoSmithKline have an interest in buying the biotech now that its leukemia drug Iclusig is back on the market, with shares 50% lower than where they were before its safety issues were known.
In this video from Friday's Market Checkup, David looks at two questions about the stock, and the biotech business as a whole. He discusses, why even when battling a very serious disease such as leukemia, some drugs should be reserved as a last resort, and he tells investors how giant companies can mitigate risk by licensing drugs from much smaller companies, such as Ariad.
The best way to play the biotech space today?
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In The Motley Fool's brand-new free report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.
The article All Questions Answered for Ariad Pharmaceuticals Inc. originally appeared on Fool.com.David Williamson owns shares of Johnson & Johnson and Novartis. Follow David on Twitter: @MotleyDavid.The Motley Fool recommends GlaxoSmithKline and Johnson & Johnson and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.